- Details
- Jeremy Teoh joins Ashish Kamat, providing a clinical perspective on recurrence mechanism of non-muscle invasive bladder cancer (NMIBC). The oncological control of NMIBC is often challenging, and the recurrence rates can be high. Dr. Teoh emphasizes the importance of understanding the mechanisms of recurrence, and in this discussion with Ashish Kamat highlights the following five mechanisms: undete...
|
- Details
- Neal Shore joins Alicia Morgans to discuss the benefits of Blue light cystoscopy (BLC) when patients receive this option for bladder cancer care in ambulatory surgery centers. BLC enhances urologists' ability to detect cancerous tissue, leading to more complete resection and reduced costs for the US healthcare system. Reimbursement for outpatient ambulatory surgery centers or clinics could be more...
|
- Details
- Kyle Rose joins Sam Chang in discussing his team's findings regarding the impact of cell-free urinary DNA on non-muscle invasive bladder cancer patients. This study aims to detect tumor alterations or mutations in the urine of high-risk non-invasive bladder cancer patients undergoing a repeat TURBT. Using whole exome sequencing and an ultra-deep sequencing platform, the study found that urinary tu...
|
- Details
- At the 2022 Large Urology Group Practice Association (LUGPA) annual CME meeting, Colin Dinney presented on the explosion of intravesical therapy for non-muscle invasive bladder cancer (NMIBC). Biography: Colin P. N. Dinney, MD, Chairman, Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Related Content: EAU 2022: State-of-the-art Lectur...
|
- Details
- In this discussion, Max Kates and Trinity Bivalacqua join Ashish Kamat in reviewing Blue Light Cystoscopy (BLC®) with Cysview®, specifically highlighting the New Blue Light Powered by Saphira® providing next-level visualization being used with Photocure’s Cysview® product in BLC® procedures for the detection of non‐muscle invasive bladder cancer (NMIBC). The new Blue Light system was approved on F...
|
- Details
- Petros Grivas welcomes Karim Chamie to discuss the exciting developments in urothelial cancer, focusing on the QUILT trial involving BCG unresponsive, high-risk non-muscle invasive bladder cancer patients. Dr. Chamie shares insights into historical treatments, the limitations of current approaches, and the breakthroughs achieved by combining intravesical BCG with the Interleukin-15 super agonist,...
|
- Details
- Intravesical Bacillus Calmette-Guérin (BCG) is an efficacious treatment for non-muscle-invasive bladder cancer (NMIBC) and was the first therapy to reduce the risk of recurrence and progression in high-risk NMIBC. Depending on risk, approximately 70% of patients may achieve a complete response to BCG; however, up to 60% may experience recurrence after 1 year. For some clinics and their patients, t...
|
- Details
- Patrick Soon-Shiong joins Ashish Kamat in a discussion on the mechanism of action of N-803 (Anktiva TM ) + BCG Inducing Durable Complete Response in BCG Unresponsive NMIBC. N-803 is a novel IL-15 superagonist complex consisting of an IL-15 mutant (IL-15N72D) bound to an IL-15 receptor α/IgG1 Fc fusion protein. Dr. Soon-Shiong summarizes the May 2021 phase 1 publication Safety, Tolerability, and Lo...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the KEYNOTE-057 study. The KEYNOTE-057 study sought to assess whether pembrolizumab could induce the clinical complete response in patients with BCG-unresponsive high-risk NMIBC. Standard treatment for high-risk non-muscle-invasive bladder cancer (NMIBC) is transurethral resection of bladder tumor followed by intravesical Bacillus Calmette-Guerin (BC...
|
- Details
- Sam Chang joins Ashish Kamat to discuss the results of the QUILT study, which he presented at the GU ASCO 2022 annual meeting. QUILT 3.032 is an open-label, multicenter phase 3 study of intravesical bacillus calmette-guerin (BCG) plus N-803 in patients with BCG-unresponsive high-grade non-muscle-invasive bladder cancer (NMIBC) (NCT03022825) with CIS and papillary disease. Given the observed strong...
|
